Unknown

Dataset Information

0

A phase I/II study of brentuximab vedotin + AVD in paediatric patients with advanced Hodgkin lymphoma.

ABSTRACT:

SUBMITTER: Salvino MA 

PROVIDER: S-EPMC12710109 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown P101 (0149) PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN PLUS AVD IN PEDIATRIC PATIENTS WITH ADVANCED STAGE NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA
| S-EPMC8925847 | biostudies-literature
Unknown Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.
| S-EPMC5025897 | biostudies-literature
Unknown Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort.
| S-EPMC10628810 | biostudies-literature
Unknown Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial.
| S-EPMC10859222 | biostudies-literature
Unknown Brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone for advanced-stage Hodgkin lymphoma in older patients.
| S-EPMC12358935 | biostudies-literature
Unknown Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.
| S-EPMC5832596 | biostudies-literature
Unknown Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.
| S-EPMC4692140 | biostudies-literature
Unknown Optimizing Brentuximab Vedotin Dosing in Pediatric Patients with Advanced Hodgkin Lymphoma: A Population Pharmacokinetic and Exposure-Response Analysis.
| S-EPMC12087681 | biostudies-literature
Unknown The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma.
| S-EPMC6910100 | biostudies-literature
Unknown Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma.
| S-EPMC10338202 | biostudies-literature